SG Americas Securities LLC Boosts Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

SG Americas Securities LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 117.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 26,841 shares of the biopharmaceutical company's stock after buying an additional 14,475 shares during the quarter. SG Americas Securities LLC's holdings in Halozyme Therapeutics were worth $1,713,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in HALO. Venturi Wealth Management LLC bought a new stake in Halozyme Therapeutics during the 4th quarter valued at $69,000. D. E. Shaw & Co. Inc. lifted its stake in shares of Halozyme Therapeutics by 171.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock worth $39,750,000 after purchasing an additional 524,802 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Halozyme Therapeutics by 0.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock valued at $85,254,000 after purchasing an additional 9,780 shares in the last quarter. Rhumbline Advisers grew its stake in Halozyme Therapeutics by 1.4% in the fourth quarter. Rhumbline Advisers now owns 410,508 shares of the biopharmaceutical company's stock valued at $19,626,000 after purchasing an additional 5,833 shares during the last quarter. Finally, Two Sigma Advisers LP purchased a new position in Halozyme Therapeutics in the fourth quarter valued at about $282,000. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Trading Down 1.5%

Halozyme Therapeutics stock traded down $0.81 during trading on Tuesday, reaching $53.11. 1,629,430 shares of the company were exchanged, compared to its average volume of 1,633,057. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $70.51. The company has a market capitalization of $6.54 billion, a P/E ratio of 12.72, a PEG ratio of 0.36 and a beta of 1.19. The stock's 50 day simple moving average is $57.27 and its two-hundred day simple moving average is $56.22. The company has a debt-to-equity ratio of 3.13, a current ratio of 8.39 and a quick ratio of 7.30.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. The business had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. During the same quarter last year, the firm earned $0.79 EPS. The business's revenue was up 35.2% compared to the same quarter last year. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on HALO shares. HC Wainwright restated a "buy" rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a report on Thursday, May 29th. JPMorgan Chase & Co. lifted their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Leerink Partnrs lowered Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Benchmark cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Finally, Wells Fargo & Company upped their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $61.90.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 503 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total value of $32,217.15. Following the completion of the sale, the director now owns 33,108 shares in the company, valued at approximately $2,120,567.40. This trade represents a 1.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.90% of the stock is owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.